Supernus and Indivior complete merger to create diversified CNS biopharmaceutical company
Supernus and Indivior have completed a merger of equals, creating a diversified central nervous system biopharmaceutical company with an 11-product portfolio spanning addiction treatment, psychiatry and neurology.
The transaction, completed on 2 November 2026, establishes Supernus Inc. as the combined business, with former Indivior shareholders holding approximately 56.5% and former Supernus shareholders holding approximately 43.5% of the company.
Under the merger terms, Supernus shareholders received 1.5401 Indivior shares for each share held, while legacy Indivior shareholders received an aggregate $1 billion special cash dividend, with the combined company scheduled to begin trading under the SUPN ticker on 3 November.
Field | Content |
Article Type | Deals |
Company | Supernus Inc. |
Merger Parties | Supernus Pharmaceuticals; Indivior |
Deal Type | Completed merger of equals |
Transaction Status | Completed |
Completion Date | 2 November 2026 |
Combined Company Name | Supernus Inc. |
Therapeutic Focus | Central nervous system disorders |
Therapeutic Areas | Opioid use disorder; psychiatry; neurology |
Combined Product Portfolio | 11 products |
Former Indivior Shareholder Ownership | Approximately 56.5% |
Former Supernus Shareholder Ownership | Approximately 43.5% |
Share Exchange Ratio | 1.5401 Indivior shares for each Supernus share |
Special Cash Dividend | Aggregate $1 billion to legacy Indivior shareholders |
Stock Ticker | SUPN |
Expected Trading Commencement | 3 November 2026 |
Geographic Scope | Not specified in supplied summary |
Transaction Valuation | Not confirmed in supplied summary |
What Happened | Supernus and Indivior completed a merger of equals to establish a diversified CNS-focused biopharmaceutical company. |
Why It Matters | The combination brings together an 11-product portfolio across addiction medicine, psychiatry and neurology, creating a broader commercial and therapeutic platform. |
Strategic Rationale | Combine complementary CNS portfolios and commercial capabilities within a single biopharmaceutical organisation. |
Financial Structure | Equity exchange with a 1.5401 share exchange ratio and an aggregate $1 billion special cash dividend to legacy Indivior shareholders. |
Key Takeaway | The merger is complete, with former Indivior shareholders owning approximately 56.5% and former Supernus shareholders approximately 43.5% of the combined company. |
What to Watch | Post-merger integration, product portfolio performance, commercial execution, financial guidance and trading under the SUPN ticker. |
Primary Source | Supernus Pharmaceuticals |
Primary Source URL | https://ir.supernus.com/news-releases/news-release-details/supernus-and-indivior-complete-merger-creating-diversified-cns |
Relevant Date | 2 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare